Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Meclofenamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 7/20 | 0.97 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.97 |
| ▸ | TTR | P02766 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 2/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.97 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.97 |
| ▸ | FABP2 | P12104 | 1/20 | 0.97 |
| ▸ | RXRA | P19793 | 1/20 | 0.97 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.97 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.97 |
| ▸ | PDE4A | P27815 | 1/20 | 0.97 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.97 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.97 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.97 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meclofenamic Acid SCHEMBL106 | 0.99 | PTGS2 (1.00) | PTGS2TTRMEN1MAPK1KMT2A | |
| Meclofenamic Acid SCHEMBL29373906 | 0.99 | PTGS2 (1.00) | PTGS2TTRMEN1MAPK1KMT2A | |
| Meclofenamic Acid SCHEMBL29379636 | 0.99 | PTGS2 (1.00) | PTGS2TTRMEN1MAPK1KMT2A | |
| Meclofenamic Acid SCHEMBL11543781 | 0.99 | PTGS2 (1.00) | PTGS2TTRMEN1MAPK1KMT2A | |
| Meclofenamic Acid SCHEMBL17200177 | 0.97 | PTGS2 (0.97) | PTGS2TTRMEN1MAPK1KMT2A | |
| Meclofenamic Acid SCHEMBL8927120 | 0.97 | PTGS2 (0.97) | PTGS2TTRMEN1MAPK1KMT2A | |
| Meclofenamic Acid SCHEMBL8193707 | 0.90 | PTGS2 (0.83) | PTGS2TTRMEN1MAPK1KMT2A | |
| Meclofenamic Acid SCHEMBL18171844 | 0.90 | PTGS2 (0.90) | PTGS2TTRMEN1MAPK1KMT2A | |
| Meclofenamic Acid SCHEMBL436190 | 0.90 | PTGS2 (0.83) | PTGS2TTRMEN1MAPK1KMT2A | |
| SCHEMBL16689763 | 0.90 | PTGS2 (0.83) | PTGS2TTRMEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114177133-B | Drug sustained-release carrier, sustained-release drug composition and application thereof | 中国医学科学院北京协和医院 | 2023-02-21 | — | — | CN | claimed |
| US-20210041441-A1 | DISCOVERY OF NOVEL MOLECULES AND REPURPOSED DRUGS FOR RAS FAMILY GTPases | UNM RAINFOREST INNOVATIONS (US) | 2021-02-11 | — | — | US | claimed |
| WO-2019173683-A1 | DISCOVERY OF NOVEL MOLECULES AND REPURPOSED DRUGS FOR RAS FAMILY GTPASES | STC. UNM (US) | 2019-09-12 | — | — | WO | claimed |
| WO-2008069546-A1 | ORAL ADMINISTRATIVE PREPARATION FOR TREATING CARDIOVASCULAR SYSTEM DISEASE | BORYUNG PHARMACEUTICAL CO., LTD (KR) | 2008-06-12 | — | — | WO | claimed |
| CN-122079986-A | Salts of compounds and crystalline forms thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-115380030-B | N-heteroarylalkyl-2- (heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2025-05-16 | — | — | CN | disclosed |
| CN-119585238-A | N- (pyrrolidin-3-yl or piperidin-4-yl) acetamide derivatives | 武田药品工业株式会社 | 2025-03-07 | — | — | CN | disclosed |
| CN-114369093-B | Salts of compounds and crystalline forms thereof | 和记黄埔医药（上海）有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-114044776-B | Salts of compounds and crystalline forms thereof | 和记黄埔医药（上海）有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-118986994-A | Agents and methods for modulating pathogen activity | 格里菲斯大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-118766866-A | Methods for improving solubility and bioavailability of therapeutic agents | 玛亚实验室公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-115215886-B | Compounds and compositions as endosomal Toll-like receptor inhibitors | 诺华股份有限公司 | 2024-10-11 | — | — | CN | disclosed |
| EP-1392261-A2 | DELIVERY OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS THROUGH AN INHALATION ROUTE | Alexza Molecular Delivery Corporation (US) | 2004-03-03 | — | — | EP | disclosed |
| CN-1102852-C | Administration media for analygesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compsns. containing such media and drugs | PITMY INTERNAT N V (AN) | 2003-03-12 | — | — | CN | disclosed |
| US-20030000518-A1 | Delivery of nonsteroidal antiinflammatory drugs through an inhalation route | ALEXZA PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| WO-2002094246-A2 | DELIVERY OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS THROUGH AN INHALATION ROUTE | ALEXZA MOLECULAR DELIVERY CORPORATION (US) | 2002-11-28 | — | — | WO | disclosed |
| CN-1228697-A | Method for in vivo reduction of iron levels and compositions useful therefor | MEDINOX INC (US) | 1999-09-15 | — | — | CN | disclosed |
| CN-1205641-A | Administration medium for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such medium and drugs | PITMY INT NV (AN) | 1999-01-20 | — | — | CN | disclosed |
| US-5686589-A | Esters and amides of substituted phenyl and pyridyl amino carboxylates | CELL PATHWAYS, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0485171-A2 | Esters and amides of substituted phenyl and pyridyl amino carboxylates | FGN, INC. (US) | 1992-05-13 | — | — | EP | disclosed |